Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 2/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | MARS1 | P56192 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105634 | 0.89 | CNR1 (0.64) | CNR1NR4A2KDM4ENPC1CRHBP | |
| SCHEMBL5102816 | 0.82 | CNR1 (0.56) | CNR1NR4A2KDM4ENPC1CRHBP | |
| SCHEMBL5098772 | 0.76 | NR4A2 (0.60) | CNR1NR4A2KDM4ENPC1RAB9A | |
| SCHEMBL5105879 | 0.74 | CNR1 (0.54) | CNR1CNR2 | |
| SCHEMBL5106206 | 0.72 | CNR1 (0.56) | CNR1KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5358199 | 0.70 | CNR1 (0.70) | CNR1SRD5A2CNR2MARS1 | |
| SCHEMBL4463174 | 0.70 | CNR1 (0.64) | CNR1SRD5A2MARS1 | |
| SCHEMBL5043907 | 0.70 | CNR1 (0.65) | CNR1KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL4807852 | 0.70 | CNR1 (0.48) | CNR1KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL4453192 | 0.70 | CNR1 (0.64) | CNR1SRD5A2MARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320978-B2 | Oxazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | OXA1L, ARG2, CYP3A7 | CNR1 246/4885NR4A2 1444/4885KDM4E 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.